Active substance
Alclometasone
- US FDA 8
- UK MHRA 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ALCLOMETASONE DIPROPIONATE | 0.05% | ointment · topical | SUN PHARMA CANADA | Prescription | 29 Jul 2004 |
| ALCLOMETASONE DIPROPIONATE | 0.05% | cream · topical | FOUGERA PHARMS | Prescription | 12 Jul 2005 |
| ALCLOMETASONE DIPROPIONATE | 0.05% | ointment · topical | FOUGERA PHARMS | Prescription | 18 Jul 2005 |
| ALCLOMETASONE DIPROPIONATE | 0.05% | cream · topical | SUN PHARMA CANADA | Prescription | 15 Sep 2005 |
| ACLOVATE | 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ointment · topical | FOUGERA | Discontinued | 14 Dec 1982 |
| ACLOVATE | 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | cream · topical | FOUGERA | Discontinued | 14 Dec 1982 |
| ALCLOMETASONE DIPROPIONATE | 0.05% | cream · topical | GLENMARK PHARMS LTD | Discontinued | 23 Jun 2009 |
| ALCLOMETASONE DIPROPIONATE | 0.05% | ointment · topical | GLENMARK PHARMS LTD | Discontinued | 30 Jul 2009 |
UK MHRA United Kingdom — marketing authorisations
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| ALCLOMETASONE DIPROPIONATE 0.05% W/W CREAM | PL 35533/0078 | ASPIRE PHARMA LIMITED | POM |
| MODRASONE OINTMENT | PL 35533/0096 | ASPIRE PHARMA LIMITED | POM |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.